Daewoong Pharmaceutical Co., Ltd (KRX:069620)

Market Cap	2.02T
Revenue (ttm)	1.54T
Net Income (ttm)	93.19B
Shares Out	11.51M
EPS (ttm)	8,098.35
PE Ratio	21.65
Forward PE	12.17
Dividend	600.00 (0.36%)
Ex-Dividend Date	Dec 29, 2025

Volume	25,170
Average Volume	70,953
Open	169,200
Previous Close	165,400
Day's Range	166,000 - 174,900
52-Week Range	109,000 - 181,400
Beta	0.46
RSI	68.46
Earnings Date	Nov 14, 2025

About Daewoong Pharmaceutical

Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1945
• Employees: 1,644
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 069620

Financial Performance

In 2024, Daewoong Pharmaceutical's revenue was 1.42 trillion, an increase of 3.44% compared to the previous year's 1.38 trillion. Earnings were 24.73 billion, a decrease of -79.68%.